Guardant Executive and Leadership Team

AmirAli Talasaz, the Co-Founder & Co-Chief Executive Officer at Guardant, directs the overarching corporate strategy and long-term vision for precision oncology diagnostics. By overseeing the development of rare-cell analysis platforms, the Co-Founder & Co-Chief Executive Officer ensures the company maintains a competitive edge in the global health services market. AmirAli Talasaz drives the integration of advanced genomic testing into standard clinical workflows, enabling physicians to identify targeted treatment alternatives for cancer patients. This leadership role involves constant collaboration with the Board to scale operations and expand the reach of diagnostic services. Through rigorous oversight of research initiatives, the Co-Founder & Co-Chief Executive Officer secures the company's position as a leader in cancer diagnostics. Ultimately, Talasaz fosters innovation to improve patient outcomes across diverse healthcare systems.

Mika Takaki, the General Manager and President at Guardant, executes the operational strategy for regional market expansion and commercial success. Overseeing the day-to-day business functions, the General Manager and President ensures that diagnostic services reach healthcare providers efficiently. Mika Takaki drives the implementation of sales and distribution models that allow physicians to access critical cancer testing reports. This leadership role involves coordinating cross-functional teams to optimize service delivery and market penetration. By managing regional operations, the General Manager and President supports the company's goal of making precision diagnostics accessible to a broader patient population. Takaki monitors performance metrics to ensure that commercial activities align with corporate objectives, ultimately strengthening the company's market position. Through strategic oversight of regional initiatives, the General Manager and President ensures consistent service quality and operational excellence.

Darya Chudova, the Chief Technology Officer at Guardant, architects the technical infrastructure required for high-throughput genomic sequencing and rare-cell diagnostics. Overseeing the engineering and data science teams, the Chief Technology Officer ensures the accuracy and reliability of testing reports provided to medical professionals. Darya Chudova drives the development of proprietary algorithms that detect cancer markers, directly impacting the efficacy of treatment selection for patients. This role involves managing complex R&D pipelines to refine diagnostic sensitivity and specificity. By aligning technical capabilities with clinical requirements, the Chief Technology Officer supports the company's mission to provide precise, actionable data. Chudova maintains the integrity of the diagnostic platform while scaling computational resources to meet increasing demand for oncology testing services across North American and international markets.

Craig Eagle, the Chief Medical Officer at Guardant, leads clinical strategy and medical affairs to ensure diagnostic services meet the highest standards of patient care. Overseeing interactions with the medical community, the Chief Medical Officer validates the clinical utility of testing reports for oncologists. Craig Eagle drives the adoption of precision medicine by translating complex genomic data into clear treatment alternatives for cancer patients. This leadership role involves managing clinical trials and regulatory engagement to support the expansion of diagnostic applications. By bridging the gap between laboratory innovation and bedside application, the Chief Medical Officer ensures that medical practices remain informed by the latest diagnostic advancements. Eagle maintains strong relationships with healthcare providers to optimize the integration of these services into standard oncology protocols, ultimately enhancing the quality of care for patients globally.

Terilyn Monroe, the Chief People Officer at Guardant, directs human capital strategy to attract and retain top-tier talent within the competitive diagnostics industry. Overseeing organizational development and culture, the Chief People Officer ensures that the workforce remains aligned with the company's mission to transform cancer care. Terilyn Monroe drives initiatives focused on professional growth, diversity, and operational efficiency across all departments. This leadership role involves partnering with the executive team to build a high-performance environment capable of supporting rapid innovation in rare-cell diagnostics. By implementing robust talent management systems, the Chief People Officer secures the human resources necessary for scaling operations. Monroe fosters a collaborative workplace that empowers employees to deliver critical testing services to physicians, thereby supporting the company's long-term growth and commitment to improving patient health outcomes.